Article

Power modulation upgrade takes phaco to new level

New Orleans-WhiteStar, the new power modulation technology for the Sovereign System (Allergan), affords phacoemulsification surgeons improved intraoperative control and optimizes outcomes for patients, with clearer corneas on postoperative day 1, said Lisa Brothers Arbisser, MD, at the annual meeting of the American Academy of Ophthalmology here last fall.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
Related Content
Q&A: David S. Boyer, MD, on the suprachordial delivery of gene therapy
June 5th 2025

Q&A: David S. Boyer, MD, on the suprachordial delivery of gene therapy

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Ocugen signs term sheet for korean licensing of OCU400 gene therapy
June 5th 2025

Ocugen signs term sheet for korean licensing of OCU400 gene therapy

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

iVeena submits IND to FDA for phase 2 clinical trial for pediatric myopia
June 4th 2025

iVeena submits IND to FDA for phase 2 clinical trial for pediatric myopia

(Image credit: AdobeStock/RFBSIP) The impact of preservatives on the ocular surface in patients with ocular hypertension or glaucoma
June 4th 2025

The impact of preservatives on the ocular surface in patients with ocular hypertension or glaucoma

© 2025 MJH Life Sciences

All rights reserved.